Principal Research Associate, Cell Therapy Islet
Sana Biotechnology, Inc.Highlight
Summary
About the Role
About You
- MSc or BSc in Stem cell biology, biochemical/biomedical Engineering or related fields with 2-4 years (MSc) or 3-5 years (BSc) of direct cell therapy industry experience.
- Experience in operating bioreactors and 3D directed differentiation.
- Significantly experienced in Flow cytometry, Immunofluorescent staining, ddPCR.
- Proficient with standard flow cytometry and imaging software (e.g. FACSDiva, FlowJo, ImageJ, Halo, etc.).
- Significantly experienced and knowledgeable in operating various types of bioreactors for suspension culture.
- Significantly experienced in operating a closed system cell culture for cell therapy.
Benefits
- Generous health coverage for employees.
- Ample time-off including holidays, vacation, sick time, and parental leave.
- Short- and long-term disability insurance.
- Employer paid basic life insurance and additional voluntary life insurance protection.
- Financial wellness programs including financial planning resources.
- 401(k) Plan with an immediately vested employer match.
- Tuition Reimbursement and Student Loan Repayment.
- Employee Stock Purchase Plan and commuter subsidy.
- Variety of wellness offerings.
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.